Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Immunotherapy in NSCLC: a perspective

Giorgio Scagliotti • 11 Apr 2018
ELCC 2018
Lung Cancer Non-Small Cell Lung Cancer

Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, provides an overview of recent trial data concerning the immunotherapy of non-oncogene addicted non-small cell lung cancer (NSCLC). Dr Scagliotti emphasizes the importance of exploring combinations of immunotherapy and other treatment modalities in a clinical setting.

More from Giorgio Scagliotti

1:32
The IASLC: implementing personalized medicine in lung cancer
Giorgio Scagliotti • 3 Jul 2019
1:46
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
Giorgio Scagliotti • 3 Jul 2019
1:53
Overcoming the challenges of precision medicine in lung cancer
Giorgio Scagliotti • 3 Jul 2019
3:23
More evidence needed to support checkpoint inhibitor use in late-stage cancer
Giorgio Scagliotti • 18 Jan 2019

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals